Advertisement

European Journal of Clinical Pharmacology

, Volume 69, Issue 11, pp 1875–1881 | Cite as

Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma

  • Jovan P. AntovicEmail author
  • Mika Skeppholm
  • Jaak Eintrei
  • Elisabet Eriksson Boija
  • Lisbeth Söderblom
  • Eva-Marie Norberg
  • Liselotte Onelöv
  • Yuko Rönquist-Nii
  • Anton Pohanka
  • Olof Beck
  • Paul Hjemdahl
  • Rickard E. Malmström
Clinical Trial

Abstract

Background

Dabigatran is an oral direct thrombin inhibitor for which routine laboratory monitoring is currently not recommended. However, there are situations in which measurements of the drug and its effect are desirable. We therefore compared and validated different coagulation methods for assessments of dabigatran in clinical samples in relation to measurements of plasma dabigatran, without the purpose of establishing effective and safe concentrations of dabigatran in plasma.

Methods

Samples were obtained from 70 atrial fibrillation patients treated with dabigatran etexilate. Plasma concentrations were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and were compared with coagulation methods Hemoclot thrombin inhibitors (HTI) and Ecarin clotting assay (ECA), as well as with prothrombin time-international normalized ratio (PT-INR) and activated partial thromboplastin time (aPTT).

Results

A wide range of dabigatran concentrations was determined by LC-MS/MS (<0.5–586 ng/mL). Correlations between LC-MS/MS results and estimated concentrations were excellent for both HTI and ECA overall (r2 = 0.97 and 0.96 respectively, p < 0.0001), but the precision and variability of these assays were not fully satisfactory in the low range of dabigatran plasma concentrations, in which ECA performed better than HTI. aPTT performed poorly, and was normal (<40 s) even with dabigatran levels of 60 ng/mL. PT-INR was normal even at supratherapeutic dabigatran concentrations.

Conclusion

LC-MS/MS is the gold standard for measurements of dabigatran in plasma. Alternatively, either HTI or ECA assays may be used, but neither of these assays is dependable when monitoring low levels or to infer total absence of dabigatran. The aPTT assay is relatively insensitive to dabigatran, and normal aPTT results may be observed even with therapeutic dabigatran concentrations.

Keywords

Dabigatran Drug concentration LC-MS/MS Hemoclot ECA PT-INR aPTT 

Notes

Conflicts of interest

JPA has received support for attendance at scientific meetings from Stago. None of the other authors declare any conflict of interest.

Contributions to the manuscript

JPA – responsible for the study design, data analysis and interpretation and writing the manuscript.

MS – providing samples, helped in research ethics application, data analysis and reviewing the manuscript.

JE – responsible for the technical installation and evaluation of the HTI assay in the laboratory, data analysis and reviewing the manuscript.

EEB – responsible for the technical installation and evaluation of the ECA assay in the laboratory, data analysis and reviewing the manuscript.

LS – responsible for laboratory analysis of HTI, handling of the study samples and reviewing the manuscript.

EMN – responsible for laboratory analysis of ECA, handling of the study samples and reviewing the manuscript.

LO – performing of some assays, data analysis and reviewing the manuscript.

YR – laboratory analysis of dabigatran concentration, handling of the study samples and reviewing the manuscript.

AP – performing of some assays, data analysis and reviewing the manuscript.

OB – responsible for the LC-MS/MS assay for determination of dabigatran concentration and reviewing of the manuscript.

PH – helped in the study design and interpretation of data and reviewed the manuscript.

REM – responsible for the study design, research ethics application, data analyses and interpretation, writing and reviewing of the manuscript.

References

  1. 1.
    Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15(Suppl 1):9S–16SPubMedCrossRefGoogle Scholar
  2. 2.
    Stangier J, Rathgen K, Stähle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292–303PubMedCrossRefGoogle Scholar
  3. 3.
  4. 4.
    Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. doi: 10.1111/jth.12149 Google Scholar
  5. 5.
    Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor Dabigatran etexilate. Clin Pharmacokinet 47:285–295PubMedCrossRefGoogle Scholar
  6. 6.
  7. 7.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo- controlled, crossover study in healthy subjects. Circulation 124:1573–1579PubMedCrossRefGoogle Scholar
  8. 8.
    Levi M, Eerenberg E, Kamphuisen PW (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9:1705–1712PubMedCrossRefGoogle Scholar
  9. 9.
    Wienen W, Stassen JM, Priepke H et al (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor Dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98:155–162PubMedGoogle Scholar
  10. 10.
    van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127PubMedCrossRefGoogle Scholar
  11. 11.
    Lindahl TL, Baghaei F, Blixter IF et al (2010) Effects of the oral, direct thrombin inhibitor Dabigatran on five common coagulation assays. Thromb Haemost 105:371–378PubMedCrossRefGoogle Scholar
  12. 12.
    Freyburger G, Macouillard G, Labrouche S et al (2011) Coagulation parameters in patients receiving Dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127:457–465PubMedCrossRefGoogle Scholar
  13. 13.
    Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM (2012) Impact of Dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of Dabigatran etexilate. Thromb Haemost 107:985–997PubMedCrossRefGoogle Scholar
  14. 14.
    Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L (2013) Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem Feb 1. [Epub ahead of print]Google Scholar
  15. 15.
    Samama MM, Guinet C, Le Flem L, Ninin E, Debue JM (2013) Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 35:140–146PubMedCrossRefGoogle Scholar
  16. 16.
    Baglin T, Keeling D, Kitchen S (2012) Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral Dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 159:427–429PubMedCrossRefGoogle Scholar
  17. 17.
    (2001) Guidance for industry: bioanalytical method validation. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, MDGoogle Scholar
  18. 18.
    Tripodi A (2013) The laboratory and the new oral anticoagulants. Clin Chem 59:353–362PubMedCrossRefGoogle Scholar
  19. 19.
    Lillo-Le Louët A, Wolf M, Soufir L et al (2012) Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost 108:583–585PubMedCrossRefGoogle Scholar
  20. 20.
    Avecilla ST, Ferrell C, Chandler WL, Reyes M (2012) Plasma-diluted thrombin time to measure Dabigatran concentrations during Dabigatran etexilate therapy. Am J Clin Pathol 137:572–574PubMedCrossRefGoogle Scholar
  21. 21.
    Garcia D, Barrett YC, Ramacciotti E, Weitz JI (2013) Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 11:245–252PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Jovan P. Antovic
    • 1
    • 5
    Email author
  • Mika Skeppholm
    • 2
  • Jaak Eintrei
    • 1
  • Elisabet Eriksson Boija
    • 1
    • 3
  • Lisbeth Söderblom
    • 1
  • Eva-Marie Norberg
    • 1
  • Liselotte Onelöv
    • 1
  • Yuko Rönquist-Nii
    • 4
  • Anton Pohanka
    • 4
  • Olof Beck
    • 4
  • Paul Hjemdahl
    • 4
  • Rickard E. Malmström
    • 4
  1. 1.Department of Coagulation Research, Institute for Molecular Medicine and Surgery, Karolinska Institutet, & Department of Clinical ChemistryKarolinska University HospitalStockholmSweden
  2. 2.Department of Medicine, Clinical Pharmacology Unit, Division of Cardiovascular MedicineKarolinska Institutet & Danderyd HospitalStockholmSweden
  3. 3.EQUALIS, External Quality AssessmentUppsalaSweden
  4. 4.Department of Medicine, Clinical Pharmacology Unit, Karolinska Institutet & Clinical PharmacologyKarolinska University HospitalStockholmSweden
  5. 5.Department of Molecular Medicine & Surgery, Karolinska Institutet, Clinical Chemistry L700, Karolinska University LaboratoryKarolinska University HospitalStockholmSweden

Personalised recommendations